H4-derived Anti-SARS-CoV2 RBD mAbs, human & mouse isotypes

Anti SARS-CoV-2 Spike RBD antibody

ABOUT

Specific SARS-CoV-2 Spike-RBD neutralizing recombinant antibody 

Antibody description

InvivoGen provides Anti-CoV2RBD-c1-hIgG1 and Anti-CoV2RBD-c1-mIgG2a isotypes, derived from the specific SARS-CoV-2 neutralizing recombinant monoclonal antibody (mAb) originally described as 'clone H4' [1]. They feature:

  • The variable region from 'clone H4' that specifically targets the Spike receptor-binding domain (S-RBD) of SARS-CoV-2 [1]
  • The human IgG1 or mouse IgG2a constant region

 

Clone H4 was isolated from a convalescent COVID-19 patient and subsequently, confirmed to specifically neutralize SARS-CoV-2, in vitro, by blocking the interaction between the SARS-CoV-2 S-RBD and the host receptor ACE2 [1].  Early in the pandemic, a previously characterized SARS-CoV neutralizing mAb (CR3022) against the S-RBD was rapidly found to cross-react with SARS-CoV-2 [2]. However, CR3022 does not neutralize SARS-CoV-2 possibly because, unlike clone H4, it does not target the ACE2 binding motif in the RBD [3]. Interestingly, synergistic neutralization ability was observed when clone H4 was used in combination with a different epitope-targeting antibody (clone B38) identified in the same study [1]. This makes them a potentially promising virus-targeting antibody cocktail for therapeutic and/or vaccine purposes.

InvivoGen's Anti-CoV2RBD-c1 mAbs (clone H4) have been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography, ensuring lot-to-lot reproducibility. Furthermore, Anti-CoV2RBD-c1-hIgG1 and Anti-CoV2RBD-c1-mIgG2a have been functionally validated by ELISA and/or neutralizing assays (see data below). The absence of bacterial contamination has been confirmed by cellular assays.

 

Of note, InvivoGen also offers Anti-CoV2RBD-c1-hIgG1 and Anti-CoV2RBD-c1-mIgG2a, derived from another SARS-CoV-2 neutralizing mAb (Clone H4) [1]. In-house data suggests that B38 displays better inhibition of HEK-Blue™ hACE2 cell infection by Spike-pseudotyped lentiviral particles, and clone H4 has greater sensitivity for detection by ELISA. However, depending on your application both mAbs may be suitable for the detection of Spike-RBD and neutralization of SARS-CoV-2 infection.

 

Applications

  • Detecting the presence of SARS-CoV-2 in culture supernatant and/or in serum (ELISA)
  • Flow cytometry binding assays
  • Developing neutralizing antibody cocktails against SARS-CoV-2

 

Quality control

  • Functionally validated by ELISA using a coated Spike-RBD-His fusion peptide

 

Learn more on SARS-CoV-2 Read our reviews discussing SARS-CoV-2

 

References

1. Wu, Y. et al. 2020. A non-competing pair of human neutralizing antibodies block the COVID-19 virus binding to its receptor ACE2. Science 368, 1274-1278.
2. Tian X. et al., 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections. 9(1):382-385.
3. Yuan M. et al., 2020. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. DOI: 10.1126/science.abb7269.

 

All products are for research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Applications

Detecting the presence of SARS-CoV-2 in culture supernatant and/or in serum (ELISA). Flow cytometry binding assays. Developing neutralizing antibody cocktails against SARS-CoV-2

Isotype
hIgG1
Source
CHO cells
Purification
Protein G
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative
Azide-free
Reconstitution buffer
Sterile water
Sterility

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.

Tested applications

ELISA, neutralizing assays, Flow cytometry binding assays

Quality control

The complete sequence of each antibody construct has been verified. Antibody binding has been validated by ELISA using a coated Spike-RBD-His fusion peptide. The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.

CONTENTS

Contents

  • Product: 
    Anti-CoV2RBD-c1-hIgG1
  • Cat code: 
    cov2rbdc1-mab1-3
  • Quantity: 
    3 x 100 µg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C
    Stability: Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20 °C.

    Caution:

    • Avoid repeated freeze-thaw cycles

DOCUMENTS

Documents

Anti-CoV2RBD-c1-hIgG1

Technical Data Sheet

Safety Data Sheet

Validation Data Sheet

Certificate of analysis

Need a CoA ?

Citations

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?